Login to Your Account

In The Clinic NEWS

One month after shares of Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) took a 30 percent haircut following a phase III miss by blisibimod in the lead indication of systemic lupus erythematosus (SLE), investors did an about-face on maturing data from the phase BRIGHT-SC proof-of-concept study of the same agent in individuals with IgA nephropathy (IgAN), also known as Berger's disease.

ASH 2016

SAN DIEGO – It's the best of times and the worst of times for CAR T cells.

SHANGHAI – Shanghai-based Hutchison Medipharma Co. Ltd. presented phase I data for epitinib at the World Conference on Lung Cancer in Vienna showing that epitinib is a safe EGFR inhibitor with the ability to cross the blood-brain barrier (BBB).

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: